American patients would ultimately bear the cost of President Donald Trump‘s threatened tariffs on generic drugs, the CEO of Swiss pharmaceutical company Sandoz told CNBC, warning that manufacturers could be forced to raise prices or stop supplying some medicines. “Patients pay the tariff,” Sandoz CEO Richard Saynor said in an interview with CNBC during its…
AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting hopes that it could generate multibillion-dollar sales for the company. The biologic medicine, tozorakimab, is under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027….
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial. The company’s stock was…
Blood sample for a lipoprotein(a) test. Md Babul Hosen | Istock | Getty Images Novartis‘ failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry’s biggest drug races and rival treatments from U.S. heavyweights Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly…
Stanley Druckenmiller at CNBC’s Delivering Alpha on Sept. 28, 2022. Scott Mlyn | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Investment firms of ultra-wealthy families are helping fuel the…
Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares to new highs still has room to run. In a note to clients Wednesday, analysts at UBS raised their price target on the healthcare giant to $320 per share from $280. Their bullish view is based on three factors: (1) Top-line growth inflecting from…
U.S. President Donald Trump delivers remarks on his administration’s healthcare policies, in the Oval Office at the White House in Washington, D.C., U.S., Aug. 31, 2026. Evelyn Hockstein | Reuters President Donald Trump on Monday said he struck new drug pricing deals with nine drugmakers to voluntarily sell their medications for less, building on his…
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients, the company announced Thursday. The drug, marketed as Bixlenvo, is aimed at patients whose virus is already under control but who remain on complicated treatment regimens. It could also appeal…
A Medical Assistant gives a measles, mumps and rubella, vaccination to a young person at the pediatric office of Dr. Gary M. Kramer on Aug. 13, 2026, in Coral Gables, Florida. Joe Raedle | Getty Images Record measles cases and rising childhood vaccine exemptions in the U.S. have fueled concerns that Americans are increasingly turning…
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it to compete with rival Novo Nordisk’s Wegovy pill in the U.K. It marks only the second GLP-1 weight-loss pill in the European market and comes just two months after Novo launched its Wegovy pill there. The U.K.’s…
